DK0062498333
DK0062498333
Novo Nordisk B A/S
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 | Q4 '25 31.12.2025 |
|---|---|---|---|---|
Market & Enterprise Value | ||||
Market Cap | 1.13T EUR | 1.39T EUR | 1.02T EUR | 1.45T EUR |
Enterprise Value | 1.23T EUR | 1.49T EUR | 1.15T EUR | 1.55T EUR |
Valuation Multiples | ||||
Trailing P/E | 9.74x | 11.95x | 8.4x | 19.69x |
Forward P/E | 11.68x | -- | -- | -- |
Price to Sales | 3.42x | 4.23x | 3.13x | 6.26x |
Price to Book | 5.11x | 6.29x | 5.05x | 7.45x |
EV/Revenue | 3.72x | 4.52x | 3.51x | 6.71x |
EV/EBITDA | 7.06x | 9.25x | 6.53x | 14.51x |
Price to FCF (P/FCF) | 29.91x | 29.13x | 33.17x | 76.69x |
EV/FCF | 32.53x | 31.13x | 37.23x | 82.24x |
FCF Yield | 3.34% | 3.43% | 3.01% | 1.3% |